United Therapeutics Other — Total revenues decreased by 19.7% to $5.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.0%, from $5.00M to $5.30M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates successful monetization of secondary assets or emerging business lines, while a decrease suggests a decline in non-core operations or a strategic shift away from these activities.
This metric represents the total gross income generated by the company's non-core or miscellaneous business segments tha...
Peers often report this as 'Other Revenue' or 'Non-Core Segment Revenue', which typically represents a small fraction of total corporate revenue.
uthr_segment_other_total_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $10.00M | $0.00 | $0.00 | $3.80M | $2.50M | $3.50M | $1.90M | $3.90M | $6.20M | $4.90M | $5.50M | $5.50M | $5.00M | $5.50M | $6.90M | $6.60M | $5.30M |
| QoQ Change | — | — | — | — | -100.0% | — | — | -34.2% | +40.0% | -45.7% | +105.3% | +59.0% | -21.0% | +12.2% | +0.0% | -9.1% | +10.0% | +25.5% | -4.3% | -19.7% |
| YoY Change | — | — | — | — | — | — | — | -75.0% | — | — | +2.6% | +148.0% | +40.0% | +189.5% | +41.0% | -19.4% | +12.2% | +25.5% | +20.0% | +6.0% |